Response to Treatment Series: Part 2, tumor response assessment - Using new and conventional criteria

Vahid Yaghmai; Frank H. Miller; Pedram Rezai; Al B. Benson; Riad Salem

doi:10.2214/AJR.11.6581

Response to Treatment Series: Part 2, tumor response assessment - Using new and conventional criteria

Vahid Yaghmai^*, Frank H. Miller, Pedram Rezai, Al B. Benson, Riad Salem

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

56 Scopus citations

Abstract

OBJECTIVE. Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. CONCLUSION. Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.

Original language	English (US)
Pages (from-to)	18-27
Number of pages	10
Journal	American Journal of Roentgenology
Volume	197
Issue number	1
DOIs	https://doi.org/10.2214/AJR.11.6581
State	Published - Jul 2011

Keywords

Choi criteria
EASL
Imaging biomarkers
Oncologic imaging
RECICL
RECIST
Tumor response

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2214/AJR.11.6581

Cite this

@article{463a6b2d54254f78a0abfb738ccd8abb,

title = "Response to Treatment Series: Part 2, tumor response assessment - Using new and conventional criteria",

abstract = "OBJECTIVE. Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. CONCLUSION. Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.",

keywords = "Choi criteria, EASL, Imaging biomarkers, Oncologic imaging, RECICL, RECIST, Tumor response",

author = "Vahid Yaghmai and Miller, {Frank H.} and Pedram Rezai and Benson, {Al B.} and Riad Salem",

year = "2011",

month = jul,

doi = "10.2214/AJR.11.6581",

language = "English (US)",

volume = "197",

pages = "18--27",

journal = "American Journal of Roentgenology",

issn = "0361-803X",

publisher = "American Roentgen Ray Society",

number = "1",

}

TY - JOUR

T1 - Response to Treatment Series

T2 - Part 2, tumor response assessment - Using new and conventional criteria

AU - Yaghmai, Vahid

AU - Miller, Frank H.

AU - Rezai, Pedram

AU - Benson, Al B.

AU - Salem, Riad

PY - 2011/7

Y1 - 2011/7

N2 - OBJECTIVE. Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. CONCLUSION. Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.

AB - OBJECTIVE. Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. CONCLUSION. Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.

KW - Choi criteria

KW - EASL

KW - Imaging biomarkers

KW - Oncologic imaging

KW - RECICL

KW - RECIST

KW - Tumor response

UR - http://www.scopus.com/inward/record.url?scp=79960476903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960476903&partnerID=8YFLogxK

U2 - 10.2214/AJR.11.6581

DO - 10.2214/AJR.11.6581

M3 - Comment/debate

C2 - 21701006

AN - SCOPUS:79960476903

SN - 0361-803X

VL - 197

SP - 18

EP - 27

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

IS - 1

ER -

Response to Treatment Series: Part 2, tumor response assessment - Using new and conventional criteria

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this